The reason for these conflicting reports is not entirely clear but may be related to the use of different SGLT2 inhibitors, the dose and duration of SGLT2 inhibitor treatment, and/or utilization of alternative animal models of diabetes. Here, SLC5A2 is linked to diabetes mellitus.